
Alligator Bioscience Stock Plummets Over 73% After Halting Lead Cancer Drug Program
Shares of the Swedish biotech firm collapsed after it announced it would discontinue in-house development of its pancreatic cancer drug, mitazalimab, and seek a rights issue to secure funding.







